VC Directory
11,013 venture capitalists profiled
Showing 2,581-2,640 of 11,013J/K to navigate
Dr. Friederike Hoffmann
Partner
Check: b2venture does not publish a standard current check-size range on its official site.
Be the first institutional backer of outstanding European entrepreneurs and add specialist support through an experienced angel community.
Dr. Graham Davies
Fund Principal
Check: Mercia Ventures does not publish a single standard check-size range across its managed funds.
Dr. Graham Davies invests or supports investment decisions through Mercia Ventures's published strategy: Invest across the United Kingdom in ambitious technology and life-science companies, supporting founders from first conversation through scale and exit.
Dr. Greg Burrell
Venture Partner
Check: $1M-$2M when leading pre-seed rounds; the firm also participates from pre-seed through pre-IPO.
Dr. Greg Burrell invests or supports investments through Necessary Ventures's published strategy: Back ambitious founders across deep tech, hard tech and AI who address fundamental needs in healthcare, reindustrialization, climate, finance and education.
Dr. h.c. Beate Heraeus
Strategic Advisor
Check: AENU does not publish one standard current check-size range on its official site.
Dr. h.c. Beate Heraeus supports AENU, whose published strategy is: Back ambitious European founders using market-driven technology to decarbonize industry, restore ecosystems and advance climate capitalism.
Dr. Hans-Christoph Quelle
Venture Partner
Check: €2M-€6M initially and up to €25M per company, as published by eCAPITAL.
Dr. Hans-Christoph Quelle invests or supports investments through eCAPITAL's published strategy: Back European deep-tech companies from seed through Series B in cybersecurity, AI infrastructure, climate, materials and semiconductors.
Dr. Hanspeter Fässler
Advisory Board
Check: Spicehaus Partners does not publish a standard current check-size range on its official site.
Dr. Hanspeter Fässler is listed in a Advisory Board capacity at Spicehaus Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Dr. Harald Nieder
General Partner
Check: redalpine does not publish a standard person-specific check-size range on its current site.
The official roster identifies Dr. Harald Nieder as General Partner. This profile applies redalpine's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Advise investments in European game changers where software and science combine to create technical breakthroughs, meaningful societal value and durable companies.
Dr. Heinrich Baumann
Board Member
Check: Backbone Ventures does not publish a standard current check-size range on its official site.
Back exceptional and overlooked founders in Switzerland and Germany at the earliest stages with hands-on partnership.
Dr. Holger Schlageter
Venture Partner
Check: €150K-€300K pre-seed tickets, as published by Sunfish Partners.
Dr. Holger Schlageter invests or supports investment decisions through Sunfish Partners's published strategy: Back Central and Eastern European founders building hardware and software for space, defence and European technological autonomy.
Dr. Ingo Potthof
Managing Partner
Check: Up to €10M initially, as published by UVC Partners.
Dr. Ingo Potthof invests or supports investments through UVC Partners's published strategy: Back ambitious European B2B technology founders in software, AI, deep tech, climate tech, mobility, and industrial transformation, with access to the UnternehmerTUM ecosystem.
Dr. Isabella Fandrych
General Partner
Check: Up to €1M initially, as published by Nucleus Capital.
Dr. Isabella Fandrych invests through Nucleus Capital's published strategy: Write first checks into European and US founders applying programmable biology and deep technology to food, materials and neo-industrial systems.
Dr. Isabelle Canu
Venture Circle Member
Check: Up to €15M across financing rounds; EU Tech&Scale can provide up to €30M for eligible scale-ups.
Dr. Isabelle Canu is listed in a Venture Circle Member capacity at NRW.Venture. No person-specific investment authority is inferred; the firm's mandate is included only as organizational context.
Dr. Ivonn Szeverenyi
Advisory Board
Check: €600K-€4.5M per company, as published by Vespucci Partners.
Back Central European teams with proprietary technology, real customer need and a credible path to international expansion.
Dr. Jan Blochwitz-Nimoth
Venture Partner
Check: €2M-€6M initially and up to €25M per company, as published by eCAPITAL.
Dr. Jan Blochwitz-Nimoth invests or supports investments through eCAPITAL's published strategy: Back European deep-tech companies from seed through Series B in cybersecurity, AI infrastructure, climate, materials and semiconductors.
Dr. Jan Claudio Muñoz
Partner
Check: Backbone Ventures does not publish a standard current check-size range on its official site.
Back exceptional and overlooked founders in Switzerland and Germany at the earliest stages with hands-on partnership.
Dr. Jan Wurzbacher
Advisor
Check: Übermorgen Ventures does not publish a standard current check-size range on its official site.
Dr. Jan Wurzbacher supports Übermorgen Ventures, whose published strategy is: Back early-stage European climate founders building a resilient, zero-carbon economy, with a core team supported by mission-aligned operators and scientific advisors.
Dr. Jesko Petersen
Legal Counsel
Check: Approximately €1M initial investment, as published by seed + speed Ventures.
Dr. Jesko Petersen is listed in a Legal Counsel capacity at seed + speed Ventures. No person-specific investment authority is inferred; the firm's mandate is included only as organizational context.
Dr. Jill Buban
Advisory Board Member
Check: GSV Ventures does not publish a standard current check-size range on its official site.
Dr. Jill Buban is listed in a Advisory Board Member capacity at GSV Ventures. This profile preserves that role distinction and uses the firm's mandate only as shared context.
Dr. Johannes Fischer
Managing Partner
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Johannes Fischer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Karin Lenzlinger Diedenhofen
Advisor
Check: Übermorgen Ventures does not publish a standard current check-size range on its official site.
Dr. Karin Lenzlinger Diedenhofen supports Übermorgen Ventures, whose published strategy is: Back early-stage European climate founders building a resilient, zero-carbon economy, with a core team supported by mission-aligned operators and scientific advisors.
Dr. Karl Muth
Venture Advisor
Check: $100K-$1M initial checks, as published by Overlook Ventures.
Dr. Karl Muth is listed in a Venture Advisor capacity at Overlook Ventures. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.
Dr. Lan Xuezhao
Founder & Partner
Check: $1M-$3M is common, with published checks ranging from a few hundred thousand dollars to more than $9M.
Dr. Lan Xuezhao invests or supports investments through Basis Set Ventures's published strategy: Partner from pre-seed through Series A with AI-native founders building software and infrastructure that scale human capability and reshape work.
Dr. Lauren Lentz
General Partner
Check: €1M-€3M initial investments, as published by Revent.
Dr. Lauren Lentz invests or supports investment decisions through Revent's published strategy: Back mission-driven founders at day zero applying technology to planetary and societal challenges, human flourishing and AI for society.
Dr. Lisa Gartenmann
Manager
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Lisa Gartenmann invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Lisa Hehenberger
Impact & Advisory Board Member
Check: Rubio Impact Ventures does not publish one standard current check-size range on its official site.
Dr. Lisa Hehenberger supports Rubio Impact Ventures, whose published strategy is: Back scalable European companies across People Power and Planet Paradise themes, combining venture returns with measurable social or environmental impact.
Dr. Louis-Paul Wicki
Industry Network - IT
Check: EquityPitcher Ventures does not publish a standard current check-size range on its official site.
Dr. Louis-Paul Wicki is listed in a Industry Network - IT capacity at EquityPitcher Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Dr. Luca Del Medico
Associate
Check: redalpine does not publish a standard person-specific check-size range on its current site.
The official roster identifies Dr. Luca Del Medico as Associate. This profile applies redalpine's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Advise investments in European game changers where software and science combine to create technical breakthroughs, meaningful societal value and durable companies.
Dr. Lucas Mittelmeier
Investment Team
Check: Heal Capital does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Dr. Lucas Mittelmeier.
Dr. Lucas Mittelmeier works on Heal Capital's strategy to back mission-driven European HealthTech founders with capital and access to healthcare-system expertise to improve care and patient outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Dr. Manu Kumar
Chief Firestarter
Check: $250K-$750K initial investments, with a published sweet spot around $400K.
Dr. Manu Kumar invests or supports investments through K9 Ventures's published strategy: Be the first professional investor in Bay Area technology startups led by technical founders creating a new technology or market.
Dr. Marc Moesser
Partner
Check: redalpine does not publish a standard person-specific check-size range on its current site.
The official roster identifies Dr. Marc Moesser as Partner. This profile applies redalpine's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Advise investments in European game changers where software and science combine to create technical breakthroughs, meaningful societal value and durable companies.
Dr. Marcus Erken
Co-Founder and Managing Partner
Check: €150K-€300K pre-seed tickets, as published by Sunfish Partners.
Dr. Marcus Erken invests or supports investment decisions through Sunfish Partners's published strategy: Back Central and Eastern European founders building hardware and software for space, defence and European technological autonomy.
Dr. Marek Kozlowski
Senior Investment Director, Life Science & CleanTech
Check: Up to €15M across financing rounds; EU Tech&Scale can provide up to €30M for eligible scale-ups.
Dr. Marek Kozlowski invests or supports investment decisions through NRW.Venture's published strategy: Co-invest in innovative NRW companies that have completed seed, angel or initial VC financing across technology, life sciences, climate and digital markets.
Dr. Maria Bräutigam
Investment Manager, Life Science & Cleantech
Check: Up to €15M across financing rounds; EU Tech&Scale can provide up to €30M for eligible scale-ups.
Dr. Maria Bräutigam invests or supports investment decisions through NRW.Venture's published strategy: Co-invest in innovative NRW companies that have completed seed, angel or initial VC financing across technology, life sciences, climate and digital markets.
Dr. Mark Windeknecht
Principal
Check: World Fund does not publish one standard check-size range on its current official site.
Dr. Mark Windeknecht invests through World Fund's published strategy: Back European climate technologies in energy, industry, and food and agriculture that have material emissions-reduction potential and venture-scale economics.
Dr. Markus Müschenich
Founding Partner
Check: Heal Capital does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Dr. Markus Müschenich.
Dr. Markus Müschenich works on Heal Capital's strategy to back mission-driven European HealthTech founders with capital and access to healthcare-system expertise to improve care and patient outcomes. The firm does not publish a narrower personal mandate on the cited roster.
Dr. Markus Wiedenmann
Investment Advisory Board Member
Check: €500K-€3M initial investments, as published by Realyze Ventures.
Dr. Markus Wiedenmann is listed in a Investment Advisory Board Member capacity at Realyze Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Dr. Mazen Rizk
Scientific Advisor
Check: Up to €1M initially, as published by Nucleus Capital.
Dr. Mazen Rizk supports Nucleus Capital, whose published strategy is: Write first checks into European and US founders applying programmable biology and deep technology to food, materials and neo-industrial systems.
Dr. Mel Spigelman
Venture Partner
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Mel Spigelman invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Michael Sidler
Founding Partner
Check: redalpine does not publish a standard person-specific check-size range on its current site.
The official roster identifies Dr. Michael Sidler as Founding Partner. This profile applies redalpine's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Advise investments in European game changers where software and science combine to create technical breakthroughs, meaningful societal value and durable companies.
Dr. Moritz Beissenhirtz
Investment Director, Life Sciences
Check: Brandenburg Kapital does not publish one standard check-size range on its current site.. No person-specific check range is inferred for Dr. Moritz Beissenhirtz.
Dr. Moritz Beissenhirtz works on Brandenburg Kapital's strategy to provide venture and mezzanine capital plus long-term strategic support to dynamic startups and SMEs creating technology-led growth in Brandenburg. The firm does not publish a narrower personal mandate on the cited roster.
Dr. Nachi Gupta
Venture Partner and Technical Advisor
Check: $1M-$2M when leading pre-seed rounds; the firm also participates from pre-seed through pre-IPO.
Dr. Nachi Gupta is listed in a Venture Partner and Technical Advisor capacity at Necessary Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.
Dr. Nathalie Weitemeyer
Director, Life Science and Senior Investment Manager
Check: €250K-€50M across stages, as published in Bayern Kapital's official investment criteria.
Dr. Nathalie Weitemeyer invests or supports investment decisions through Bayern Kapital's published strategy: Co-invest as a long-term anchor from pre-seed through growth in scalable high-tech and deep-tech companies with a registered office or operating site in Bavaria.
Dr. Nikolaus Raupp
Partner
Check: €5M-€10M initial-investment sweet spot and up to €50M per company, as published by DTCF.
Dr. Nikolaus Raupp invests or supports investment decisions through DeepTech & Climate Fonds's published strategy: Back Germany-based or Germany-affiliated technology companies with long development cycles, strong scientific or engineering foundations and the potential to become globally competitive technology leaders.
Dr. Nils Eiteneyer
Partner
Check: Capnamic does not publish a single standard check-size range on its current official site.
Dr. Nils Eiteneyer invests or supports investment decisions through Capnamic's published strategy: Partner early with outstanding European technology founders building category-defining companies across software, deep tech and digitally enabled markets.
Dr. Ole Wiesinger
Industry Network - Digital Health
Check: EquityPitcher Ventures does not publish a standard current check-size range on its official site.
Dr. Ole Wiesinger is listed in a Industry Network - Digital Health capacity at EquityPitcher Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Dr. Oliver Pabst
General Partner
Check: redalpine does not publish a standard person-specific check-size range on its current site.
The official roster identifies Dr. Oliver Pabst as General Partner. This profile applies redalpine's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Advise investments in European game changers where software and science combine to create technical breakthroughs, meaningful societal value and durable companies.
Dr. Oliver Schoppe
Partner
Check: Up to €10M initially, as published by UVC Partners.
Dr. Oliver Schoppe invests or supports investments through UVC Partners's published strategy: Back ambitious European B2B technology founders in software, AI, deep tech, climate tech, mobility, and industrial transformation, with access to the UnternehmerTUM ecosystem.
Dr. Patricia Bubner
Scientific Advisor
Check: Up to €1M initially, as published by Nucleus Capital.
Dr. Patricia Bubner supports Nucleus Capital, whose published strategy is: Write first checks into European and US founders applying programmable biology and deep technology to food, materials and neo-industrial systems.
Dr. Patrick Mollet
Advisory Board
Check: Spicehaus Partners does not publish a standard current check-size range on its official site.
Dr. Patrick Mollet is listed in a Advisory Board capacity at Spicehaus Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Dr. Paul Campbell
Managing Partner
Check: Not publicly specified on the official site
At the firm level, Brown Venture Group backs undervalued and under-resourced Black, Latino, and Indigenous technology founders building scalable companies.
Dr. Paul Grunow
Venture Partner
Check: €2M-€6M initially and up to €25M per company, as published by eCAPITAL.
Dr. Paul Grunow invests or supports investments through eCAPITAL's published strategy: Back European deep-tech companies from seed through Series B in cybersecurity, AI infrastructure, climate, materials and semiconductors.
Dr. Peter Hirth
Venture Partner
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Peter Hirth invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Petrissa Eckle
Advisor
Check: Übermorgen Ventures does not publish a standard current check-size range on its official site.
Dr. Petrissa Eckle supports Übermorgen Ventures, whose published strategy is: Back early-stage European climate founders building a resilient, zero-carbon economy, with a core team supported by mission-aligned operators and scientific advisors.
Dr. Rainer Strohmenger
Managing Partner
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Rainer Strohmenger invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Raymond Levitt
Senior Advisor
Check: Blackhorn Ventures does not publish a standard current check-size range on its official site.
Dr. Raymond Levitt is listed in a Senior Advisor capacity at Blackhorn Ventures. This profile preserves that role distinction and uses the firm's mandate only as shared context.
Dr. Regina Hodits
Venture Advisor
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Regina Hodits is listed in a Venture Advisor capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.
Dr. Robert Buschauer
Associate
Check: €2M-€20M initial investments, as published by Wellington Partners.
Dr. Robert Buschauer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.
Dr. Robert Hornby
Investor
Check: Mercia Ventures does not publish a single standard check-size range across its managed funds.
Dr. Robert Hornby invests or supports investment decisions through Mercia Ventures's published strategy: Invest across the United Kingdom in ambitious technology and life-science companies, supporting founders from first conversation through scale and exit.
Dr. Sarah Theinert
Director Value Creation
Check: Up to €10M initially, as published by UVC Partners.
Dr. Sarah Theinert is listed in a Director Value Creation capacity at UVC Partners. The firm does not publish a person-specific investment thesis for this role; this profile preserves the role distinction and uses the firm's mandate only as shared context.
Dr. Scott C. Hsu
Fusion Partner
Check: Lowercarbon Capital does not publish a standard current check-size range on its official site.
Dr. Scott C. Hsu invests or supports investments through Lowercarbon Capital's published strategy: Invest in companies capable of making real progress on climate by slashing emissions, removing carbon and advancing transformational energy systems.
Stay in the loop
Get a weekly digest of VC insights, new profiles, and funding rounds.